KEGG   DRUG: Susoctocog alfa
Entry
D10831                      Drug                                   
Name
Susoctocog alfa (INN);
Susoctocog alfa (genetical recombination) (JAN);
Obizur (TN)
Sequence
AIRRYYLGAV ELSWDYRQSE LLRELHVDTR FPATAPGALP LGPSVLYKKT VFVEFTDQLF
SVARPRPPWM GLLGPTIQAE VYDTVVVTLK NMASHPVSLH AVGVSFWKSS EGAEYEDHTS
QREKEDDKVL PGKSQTYVWQ VLKENGPTAS DPPCLTYSYL SHVDLVKDLN SGLIGALLVC
REGSLTRERT QNLHEFVLLF AVFDEGKSWH SARNDSWTRA MDPAPARAQP AMHTVNGYVN
RSLPGLIGCH KKSVYWHVIG MGTSPEVHSI FLEGHTFLVR HHRQASLEIS PLTFLTAQTF
LMDLGQFLLF CHISSHHHGG MEAHVRVESC AEEPQLRRKA DEEEDYDDNL YDSDMDVVRL
DGDDVSPFIQ IRSVAKKHPK TWVHYISAEE EDWDYAPAVP SPSDRSYKSL YLNSGPQRIG
RKYKKARFVA YTDVTFKTRK AIPYESGILG PLLYGEVGDT LLIIFKNKAS RPYNIYPHGI
TDVSALHPGR LLKGWKHLKD MPILPGETFK YKWTVTVEDG PTKSDPRCLT RYYSSSINLE
KDLASGLIGP LLICYKESVD QRGNQMMSDK RNVILFSVFD ENQSWYLAEN IQRFLPNPDG
LQPQDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SVGAQTDFLS VFFSGYTFKH
KMVYEDTLTL FPFSGETVFM SMENPGLWVL GCHNSDLRNR GMTALLKVYS CDRDIGDYYD
NTYEDIPGFL LSGKNVIEPR SFAQNSRPPS ASAPKPPVLR RHQRDISLPT FQPEEDKMDY
DDIFSTETKG EDFDIYGEDE NQDPRSFQKR TRHYFIAAVE QLWDYGMSES PRALRNRAQN
GEVPRFKKVV FREFADGSFT QPSYRGELNK HLGLLGPYIR AEVEDNIMVT FKNQASRPYS
FYSSLISYPD DQEQGAEPRH NFVQPNETRT YFWKVQHHMA PTEDEFDCKA WAYFSDVDLE
KDVHSGLIGP LLICRANTLN AAHGRQVTVQ EFALFFTIFD ETKSWYFTEN VERNCRAPCH
LQMEDPTLKE NYRFHAINGY VMDTLPGLVM AQNQRIRWYL LSMGSNENIH SIHFSGHVFS
VRKKEEYKMA VYNLYPGVFE TVEMLPSKVG IWRIECLIGE HLQAGMSTTF LVYSKECQAP
LGMASGRIRD FQITASGQYG QWAPKLARLH YSGSINAWST KDPHSWIKVD LLAPMIIHGI
MTQGARQKFS SLYISQFIIM YSLDGRNWQS YRGNSTGTLM VFFGNVDASG IKHNIFNPPI
VARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMQNKA ISDSQITASS HLSNIFATWS
PSQARLHLQG RTNAWRPRVS SAEEWLQVDL QKTVKVTGIT TQGVKSLLSS MYVKEFLVSS
SQDGRRWTLF LQDGHTKVFQ GNQDSSTPVV NALDPPLFTR YLRIHPTSWA QHIALRLEVL
GCEAQDLY
(Disulfide bridge: 154-180, 249-330, 528-554, 630-711, 948-974, 1015-1019, 1137-1285, 1290-1442)
  Type
Peptide
Class
Blood modifier agent
 DG02016  Hemostatics
  DG02014  Blood coagulation accelerant
   DG02013  Blood coagulation factor
Remark
Therapeutic category: 6349
ATC code: B02BD02
Chemical structure group: DG00170
Product (DG00170): D08798<JP> D05409<JP> D10227<JP> D10539<JP> D10758<JP> D10759<JP> D10760<JP> D10771<JP> D10818<JP> D10831<JP> D10842<JP>
Efficacy
Bleeding suppressant
Comment
Therapeutic area: Hemophilia A
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BD Blood coagulation factors
     B02BD02 Coagulation factor VIII
      D10831  Susoctocog alfa (INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   634  Human blood preparations
    6349  Others
     D10831  Susoctocog alfa (INN); Susoctocog alfa (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     DG00170  Blood coagulation factor VIII
      D10831  Susoctocog alfa
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10831
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10831
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10831
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     DG00170  Blood coagulation factor VIII
Other DBs
CAS: 1339940-90-7
PubChem: 319902631
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system